GE

231.8

+1.12%↑

RTX

135.35

-0.13%↓

CAT

353.49

+1.06%↑

BA

205.84

-0.2%↓

HON

222.76

+0.22%↑

GE

231.8

+1.12%↑

RTX

135.35

-0.13%↓

CAT

353.49

+1.06%↑

BA

205.84

-0.2%↓

HON

222.76

+0.22%↑

GE

231.8

+1.12%↑

RTX

135.35

-0.13%↓

CAT

353.49

+1.06%↑

BA

205.84

-0.2%↓

HON

222.76

+0.22%↑

GE

231.8

+1.12%↑

RTX

135.35

-0.13%↓

CAT

353.49

+1.06%↑

BA

205.84

-0.2%↓

HON

222.76

+0.22%↑

GE

231.8

+1.12%↑

RTX

135.35

-0.13%↓

CAT

353.49

+1.06%↑

BA

205.84

-0.2%↓

HON

222.76

+0.22%↑

Search

Ocugen Inc

Închisă

0.75 8.7

Rezumat

Modificarea prețului

24h

Curent

Minim

0.66

Maxim

0.8

Indicatori cheie

By Trading Economics

Venit

-1.5M

-15M

Vânzări

717K

1.5M

EPS

-0.05

Marjă de profit

-1,036.462

Angajați

95

EBITDA

-1.3M

-15M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+791.55% upside

Dividende

By Dow Jones

Următoarele câștiguri

7 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

28M

204M

Deschiderea anterioară

-7.95

Închiderea anterioară

0.75

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Ocugen Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

15 mai 2025, 22:52 UTC

Câștiguri
Principalele dinamici ale pieței

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15 mai 2025, 20:37 UTC

Top știri
Câștiguri

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16 mai 2025, 00:00 UTC

Market Talk

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15 mai 2025, 23:47 UTC

Market Talk

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15 mai 2025, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 mai 2025, 23:38 UTC

Market Talk

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 mai 2025, 23:14 UTC

Top știri

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15 mai 2025, 22:46 UTC

Top știri
Achiziții, Fuziuni, Preluări

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 mai 2025, 22:46 UTC

Achiziții, Fuziuni, Preluări

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15 mai 2025, 22:46 UTC

Achiziții, Fuziuni, Preluări

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15 mai 2025, 22:46 UTC

Achiziții, Fuziuni, Preluări

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 mai 2025, 21:58 UTC

Câștiguri

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15 mai 2025, 21:24 UTC

Câștiguri

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15 mai 2025, 20:56 UTC

Market Talk

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15 mai 2025, 20:54 UTC

Market Talk
Câștiguri

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15 mai 2025, 20:54 UTC

Câștiguri

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15 mai 2025, 20:51 UTC

Câștiguri

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15 mai 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15 mai 2025, 20:50 UTC

Achiziții, Fuziuni, Preluări

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15 mai 2025, 20:50 UTC

Câștiguri

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15 mai 2025, 20:47 UTC

Câștiguri

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15 mai 2025, 20:47 UTC

Câștiguri

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15 mai 2025, 20:47 UTC

Câștiguri

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15 mai 2025, 20:47 UTC

Câștiguri

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15 mai 2025, 20:37 UTC

Câștiguri

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15 mai 2025, 20:37 UTC

Câștiguri

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15 mai 2025, 20:37 UTC

Câștiguri

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15 mai 2025, 20:37 UTC

Câștiguri

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15 mai 2025, 20:26 UTC

Top știri

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15 mai 2025, 20:25 UTC

Câștiguri

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Comparație

Modificare preț

Ocugen Inc Așteptări

Obiectiv de preț

By TipRanks

791.55% sus

Prognoză pe 12 luni

Medie 6.33 USD  791.55%

Maxim 8 USD

Minim 4 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruOcugen Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

3 ratings

3

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

0.6818 / 0.74Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

No Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.